Menstrual pain and epithelial ovarian cancer risk

Purpose Menstrual pain is associated with increased production of inflammatory molecules, such as prostaglandins. Inflammation is involved in pathogenesis of several cancers, including ovarian cancer. In this study, we examined the association between menstrual pain and risk of ovarian cancer.

We conducted a case–control study with 2,028 cases of epithelial ovarian cancer and 2,091 age- and study center-matched controls. Women were asked to report the severity of menstrual pain during their twenties and thirties, when not using oral contraceptives or breastfeeding. We used an unconditional logistic regression to evaluate the association between menstrual pain and epithelial ovarian cancer risk overall, and polytomous logistic regression to evaluate whether the association differed across tumor subtypes.

Risk of ovarian cancer was increased in women with moderate (OR 1.22, 95 % CI 1.05–1.42) and severe pain (OR 1.34, 95 % CI 1.09–1.65) compared to women with no or mild pain during menstrual period. The association differed by histologic subtypes, with significant associations for severe pain with endometrioid (OR 1.64, 95 % CI 1.15–2.34) and clear cell tumors (OR 1.91, 95 % CI 1.11–3.28).

Our data suggest that moderate and severe pain during menstrual period are associated with increased risk of epithelial ovarian cancer. Due to high prevalence of menstrual pain in women of reproductive age, this observation warrants further studies.

American Cancer Society. Cancer facts & figures 2013. Atlanta (GA). 2013 Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717–721 Fathalla MF (1971) Incessant ovulation—a factor in ovarian neoplasia? Lancet 2:163 Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90:1774–1786 Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, Lurie G, Thompson PJ et al (2013) Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. Cancer Prev Res (Phila) 6:811–821 Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B et al (1993) Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. Jama 270:2813–2818 Irwin KL, Weiss NS, Lee NC, Peterson HB (1991) Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer. Am J Epidemiol 134:362–369 Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA et al (2013) Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case–control studies. Int J Epidemiol 42:579–589 Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM et al (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncol 13:385–394 Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–1467 Lentz G, Lobo R, Gershenson D et al (2012) Comprehensive gynecology Philadelphia. Elsevier, Mosby, PA Dawood MY (1990) Dysmenorrhea. Clin Obstet Gynecol 33:168–178 Benedetto C (1989) Eicosanoids in primary dysmenorrhea, endometriosis and menstrual migraine. Gynecol Endocrinol 3:71–94 Chan WY, Hill JC (1978) Determination of menstrual prostaglandin levels in non-dysmenorrheic and dysmenorrheic subjects. Prostaglandins 15:365–375 Jabbour HN, Sales KJ, Smith OP, Battersby S, Boddy SC (2006) Prostaglandin receptors are mediators of vascular function in endometrial pathologies. Mol Cell Endocrinol 252:191–200 Nigam S, Benedetto C, Zonca M, Leo-Rossberg I, Lubbert H, Hammerstein J (1991) Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoids 4:137–141 Powell AM, Chan WY, Alvin P, Litt IF (1985) Menstrual-PGF2 alpha, PGE2 and TXA2 in normal and dysmenorrheic women and their temporal relationship to dysmenorrhea. Prostaglandins 29:273–290 Bieglmayer C, Hofer G, Kainz C, Reinthaller A, Kopp B, Janisch H (1995) Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol 9:307–312 Rees MC, DiMarzo V, Tippins JR, Morris HR, Turnbull AC (1987) Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. J Endocrinol 113:291–295 Ikai K (1999) Psoriasis and the arachidonic acid cascade. J Dermatol Sci 21:135–146 Sperling RI (1995) Eicosanoids in rheumatoid arthritis. Rheum Dis Clin North Am 21:741–758 Sharon P, Stenson WF (1984) Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86:453–460 Rigas B, Goldman IS, Levine L (1993) Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122:518–523 Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183–1188 Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER (2001) Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 84:714–721 Harris HR, Cramer DW, Vitonis AF, DePari M, Terry KL (2012) Folate, vitamin B(6), vitamin B(12), methionine and alcohol intake in relation to ovarian cancer risk. Int J Cancer 131:E518–E529 Terry KL, De Vivo I, Titus-Ernstoff L, Sluss PM, Cramer DW (2005) Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol 161:442–451 Marshall RJ, Chisholm EM (1985) Hypothesis testing in the polychotomous logistic model with an application to detecting gastrointestinal cancer. Stat Med 4:337–344 Kotsopoulos J, Terry KL, Poole EM, Rosner B, Murphy MA, Hecht JL et al (2013) Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin. Int J Cancer 133:730–739 Poole EM, Merritt MA, Jordan SJ, Yang HP, Hankinson SE, Park Y et al (2013) Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. Cancer Epidemiol Biomarkers Prev 22:429–437 Chen Y, Wu PC, Lang JH, Ge WJ, Hartge P, Brinton LA (1992) Risk factors for epithelial ovarian cancer in Beijing, China. Int J Epidemiol 21:23–29 Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN et al (2003) Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case–control study. Am J Epidemiol 158:629–638 Merritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122:170–176 McGowan L, Parent L, Lednar W, Norris HJ (1979) The woman at risk for developing ovarian cancer. Gynecol Oncol 7:325–344 Purdie D, Green A, Bain C, Siskind V, Ward B, Hacker N et al (1995) Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case–control study. Survey of Women’s Health Study Group. Int J Cancer 62:678–684 Wynder EL, Dodo H, Barber HR (1969) Epidemiology of cancer of the ovary. Cancer 23:352–370 Vercellini P, Vigano P, Somigliana E, Fedele L (2013) Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol 10(5):261 Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS (2008) Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control 19:1357–1364 Missmer SA, Hankinson SE, Spiegelman D, Barbieri RL, Marshall LM, Hunter DJ (2004) Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol 160:784–796 Lundstrom V, Green K (1978) Endogenous levels of prostaglandin F2alpha and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol 130:640–646 Rees MC, Anderson AB, Demers LM, Turnbull AC (1984) Prostaglandins in menstrual fluid in menorrhagia and dysmenorrhoea. Br J Obstet Gynaecol 91:673–680 Chan WY, Dawood MY, Fuchs F (1981) Prostaglandins in primary dysmenorrhea. Comparison of prophylactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives. Am J Med 70:535–541 Hensler S, Mueller MM (2013) Inflammation and skin cancer: old pals telling new stories. Cancer J 19:517–524 Ohd JF, Nielsen CK, Campbell J, Landberg G, Lofberg H, Sjolander A (2003) Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 124:57–70 Zhou Y, Guo D, Li H, Jie S (2011) Circulating LTD4 in patients with hepatocellular carcinoma. Tumour Biol 32:139–144 Blumenkrantz MJ, Gallagher N, Bashore RA, Tenckhoff H (1981) Retrograde menstruation in women undergoing chronic peritoneal dialysis. Obstet Gynecol 57:667–670 Halme J, Hammond MG, Hulka JF, Raj SG, Talbert LM (1984) Retrograde menstruation in healthy women and in patients with endometriosis. Obstet Gynecol 64:151–154 Liu DT, Hitchcock A (1986) Endometriosis: its association with retrograde menstruation, dysmenorrhoea and tubal pathology. Br J Obstet Gynaecol 93:859–862 Auersperg N, Maines-Bandiera SL, Dyck HG (1997) Ovarian carcinogenesis and the biology of ovarian surface epithelium. J Cell Physiol 173:261–265 Murdoch WJ (1996) Ovarian surface epithelium, ovulation and carcinogenesis. Biol Rev Camb Philos Soc 71:529–543 Ju H, Jones M, Mishra G (2013) The Prevalence and Risk Factors of Dysmenorrhea. Epidemiol Rev Acknowledgments This work was supported by the National Cancer Institute at the National Institutes of Health (R01CA54419, P50CA105009, and 5T32CA009001-38), and the Department of Defense (W81XWH-10-1-0280). Conflict of interest The authors declare that they have no conflict of interest. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Babic, A., Cramer, D.W., Titus, L.J. et al. Menstrual pain and epithelial ovarian cancer risk. Cancer Causes Control 25, 1725–1731 (2014). https://doi.org/10.1007/s10552-014-0463-6 Received: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/s10552-014-0463-6